Elevian banks $5.5 million seed round to pursue 'young blood' derived anti-aging tech
A startup in San Francisco called Elevian has rounded up $5.5 million in seed cash to pursue its work on a regenerative medicine program.
The big idea here is that research at Stanford and Harvard found that “young blood” has a regenerative impact on organs. And they believe as a consequence that boosting GDF11 — growth differentiation factor 11 — could play an anti-aging role in humans.
The founders have licensed the tech they’re working on from Harvard.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
